The Role of Interleukin-20 in Paclitaxel-Associated Peripheral Neuropathy in Non-Metastatic Breast Cancer Patients Receiving Chemotherapy
- 30 November 2023
- journal article
- research article
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 24 (4) , 334-339
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- CX3CL1-mediated macrophage activation contributed to paclitaxel-induced DRG neuronal apoptosis and painful peripheral neuropathyBrain, Behavior, and Immunity, 2014
- IL-20 and IL-20R1 antibodies protect against liver fibrosisHepatology, 2014
- Inhibition of glycogen synthase kinase 3beta activity with lithium prevents and attenuates paclitaxel-induced neuropathic painNeuroscience, 2013
- Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancerInternational Journal of Clinical Oncology, 2011
- Natural History of Paclitaxel-Associated Acute Pain Syndrome: Prospective Cohort Study NCCTG N08C1Journal of Clinical Oncology, 2011
- Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapyBreast Cancer Research and Treatment, 2010
- IL-20 Is Regulated by Hypoxia-Inducible Factor and Up-Regulated after Experimental Ischemic StrokeThe Journal of Immunology, 2009
- Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: Evidence for mitochondrial dysfunctionPain, 2006
- Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy?Supportive Care in Cancer, 2005
- Motor neuropathy due to docetaxel and paclitaxelNeurology, 1996